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Abstract
Background: We have recently reported that Origanum majorana exhibits anticancer activity by promoting cell cycle
arrest and apoptosis of the metastatic MDA-MB-231 breast cancer cell line. Here, we extended our study by
investigating the effect of O. majorana on the migration, invasion and tumor growth of these cells.
Results: We demonstrate that non-cytotoxic concentrations of O. majorana significantly inhibited the migration and
invasion of the MDA-MB-231 cells as shown by wound-healing and matrigel invasion assays. We also show that O.
majorana induce homotypic aggregation of MDA-MB-231 associated with an upregulation of E-cadherin protein and
promoter activity. Furthermore, we show that O. majorana decrease the adhesion of MDA-MB-231 to HUVECs and
inhibits transendothelial migration of MDA-MB-231 through TNF-α-activated HUVECs. Gelatin zymography assay
shows that O. majorana suppresses the activities of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9). ELISA,
RT-PCR and Western blot results revealed that O. majorana decreases the expression of MMP-2, MMP-9, urokinase
plasminogen activator receptor (uPAR), ICAM-1 and VEGF. Further investigation revealed that O. majorana
suppresses the phosphorylation of IκB, downregulates the nuclear level of NFκB and reduces Nitric Oxide (NO)
production in MDA-MB-231 cells. Most importantly, by using chick embryo tumor growth assay, we also show that O.
majorana promotes inhibition of tumor growth and metastasis in vivo.
Conclusion: Our findings identify Origanum majorana as a promising chemopreventive and therapeutic candidate
that modulate breast cancer growth and metastasis.
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Introduction
Breast cancer is the leading cause of cancer-related deaths
in women worldwide. Approximately one-third of all women with
breast cancer develops metastasis and ultimately dies as a
result of the effects of the disease [1,2]. Cancer metastasis
starts in the primary tumor site when cancer cells start to
invade and degrade the basement membrane and the
extracellular matrix (ECM) (invasion) into the vascular or
lymphatic circulation and then survive in the circulation. Loss of
cell adhesion, induces the disassembly of cancer cells from the
primary tumor, disseminating them to distant sites through
blood vessels and lymphatics, and eventually leave the
circulation to establish metastasis in distant organs [3,4]. E-
cadherin, a cell–cell adhesion molecule, plays a major role in
the establishment and maintenance of normal tissue
architecture. It is expressed predominantly on the surface of
normal epithelial cells. For cancer cells to become metastatic,
they must decrease E-cadherin expression and break these
cell-cell adhesions associated and induction of cell mobility
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triggering a transition from tumorigenic (epithelial) to migratory/
invasive (mesenchymal) phenotype ending in tumor
metastasis. Hence, the expression level of the epithelial
cadherin (E-cadherin) has become an important indicator for
these transitions. Therefore, searching for agents that could
enhance E-cadherin expression may be attractive therapeutic
target for repressing the metastatic potential of cancer cells
[5,6].
Adhering of tumor cells to endothelial cells is an essential
step during cancer progression and metastasis. Several
adhesive molecules, such as intracellular adhesion molecule-1
(ICAM-1), have been identified as being responsible for the
endothelial adhesion of cancer cells [7]. While ICAM-1 was
found to be expressed at a low basal level in many cell type
including epithelial and endothelial cells [8], its expression as
well as soluble serum ICAM-1 were found to be high in
metastatic breast cancer patients [8]. Therefore, agents that
repress ICAM-1 expression in breast cancer cells and
subsequently blocks the interaction between cancer and
endothelial cells might be an important therapeutic target for
repressing the metastatic potential of cancer cells.
Angiogenesis is a complex multistep process involving
soluble factors, adhesion molecules, proteases and cytokines.
The process of tumor angiogenesis starts when tumor cells
themselves secrete and activate angiogenic factors, thereby
activating proteolytic enzymes. At this time, endothelial cells
concurrently proliferate, migrate, and differentiate. Vascular
endothelial growth factor (VEGF) is the most prominent
mediator in tumor angiogenesis that is markedly induced in
breast cancer [9]. Up-regulation of VEGF expression has been
reported in a variety of malignant human cancers including
breast, colon, lung cancers. An in situ hybridization study of
human breast samples showed high VEGF expression in the
tumor cells but not the normal duct epithelium [10]. Hence,
VEGF might be a good target in the treatment of breast cancer
patients.
Degradation of the extracellular matrix (ECM) surrounding
the primary tumor is an essential step in cancer cells invasion.
This degradation is important for tissue remodeling and
induction of angiogenesis, and is mainly mediated by specific
proteolytic enzymes systems mainly matrix metalloproteinases
(MMPs) and urokinase plasminogen activator (uPA). Among all
MMPs, upregulation of MMP-2 and MMP-9 was shown to be
associated with breast cancer metastasis and poor clinical
outcome [11]. Northern Blot analysis revealed that the level of
MMP-2 and MMP-9 mRNA transcript was higher in breast
cancer tissue compared to normal breast tissue [12]. In
addition, higher MMP-9 protein concentration was detected in
breast cancer tissue when compared to normal breast tissue
[13]. Similarly, higher protease activity for MMP-2 and MMP-9
was detected by zymography in tumor tissue compared to
normal tissue [14].
MMPs are directly activated by the serine protease plasmin,
which is activated from its proenzyme form (plasminogen) by
the serine protease urokinase-type plasminogen activator
(uPA) upon binding to cell surface receptor (uPAR).
Overexpression of uPA has been found in many tumor types
and is correlated with poor prognosis. Moreover, binding of
uPA to uPAR also induces signal transduction that allows
enhanced cell migration [11,15–17]. Therefore, regulating the
expression of ECM degradation enzymes are considered as a
therapeutic target for breast cancer.
Nuclear factor κB (NFκB), a transcription factor, is a key
player in cancer metastasis [3]. It has been shown that several
genes involved in tumor metastasis are directly regulated by
NFκB. The frequent over-expression of NFκB in tumor cells
suggests that selected tumor cells may acquire metastatic
activity by aberrant expression of metastasis relevant genes
during their progression. In fact, studies from different groups
showed that MMP-2 and MMP-9 [1,16], uPA [18,19], uPAR [20]
and ICAM-1 [21] are downstream targets of NFκB signaling
pathway.
Phytochemicals have accumulated increasing importance
with regards to their ability to decrease various tumors growth,
such as those in the breast. In regards to breast cancer,
increasing data have shown that these phytochemicals
modulate multiple pathways used by cancer cells in the
processes of cell proliferation, survival, angiogenesis, invasion,
and metastasis [9]. Disruption of one or more of these
pathways, therefore, provides an effective avenue for
therapeutic intervention of breast cancer. In this regards,
several phytochemicals have been reported to be effective in
inhibiting the invasive potential of many metastatic cancer cell
lines. Examples of such promising phytochemicals include: [6]-
gingerol [17], isothiocyanates from broccoli and watercress
[11], tea catechins [22], genistein, apigenin [23], Ganoderma
lucidum [24], and ganoderic acid from the G. lucidum [25].
Origanum majorana, commonly known as marjoram, is
spread worldwide. It is utilized as a spice and flavoring agent,
and in traditional medicine as well for the treatment of chest
infection, cough, sore throat, rheumatic pain, nervous
disorders, stomach disorders, cardiovascular diseases, and
skin care. There is increasing evidence that O. majorana
possesses extensive range of biological activity, including
antioxidant, antimicrobial, anti-inflammatory and
hepatoprotective activities [26–30]. Recently, we have shown
that Origanum majorana suppresses the growth of the triple
negative MDA-MB-231 breast cancer cells by causing cell
cycle arrest and apoptosis [31]. However, its effect against
tumor invasion and metastasis is largely unknown. In this
study, we have extended our investigation by testing the ability
of O. majorana to inhibit migration, invasion and metastasis of
the MDA-MB-231 cells.
Materials and Methods
Preparation of the Origanum majorana ethanolic extract
(OME)
Origanum marjorana ethanolic extract (OME) was prepared
as previously described [31].
Cell culture and reagents.  Human breast cancer cells
MDA-MB-231 and MDA-MB-231-GFP were maintained in
DMEM (Hyclone, Cramlington, UK). MDA-MB-23-GFP used in
this study were previously described [32]. All media were
complemented with 10% fetal bovine serum (FBS) (Hyclone,
Cramlington, UK), 100U/ml penicillin/streptomycin (Hyclone,
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Cramlington, UK). HUVECs (Invitrogen, Carlsbad, CA, USA)
were maintained in MEM 199 supplemented with 20% FBS,
penicillin/streptomycin, 2 mM L-glutamine, 5U/ml heparin and
50 µg/ml endothelial cell growth supplements (BD Biosciences,
Bedfrord, MA, USA). Antibodies to NF-κB p65 (3034), pIκB-α
(ser32) (2859) were obtained from Cell Signaling (Cell
Signaling Technology, Inc., Danvers, MA, USA). Antibodies to
ICAM-1 (sc-107), β-actin (C4, sc-47778), goat anti-mouse IgG-
HRP (sc-2005) and goat anti-rabbit IgG-HRP (sc-2004) were
obtained from Santa Cruz Biotechnology, Inc. Antibody to E-
cadherin (ab15148) and uPAR (ab 103791) were obtained from
Abcam and AlexaFluor 488 goat anti-rabbit IgG (H+L) (A11008)
was obtained from invitrogen.
Wound healing migration assay.  Wound healing assay
was performed as previously described [33]. Briefly, MDA-
MB-231 cells were grown in six-well tissue culture dishes until
confluence. A scrape was made through the confluent
monolayer with a sterile plastic pipette tip of 1mm diameter.
Afterwards, the dishes were washed twice with PBS and
incubated at 37°C in fresh DMEM complemented with 10%
fetal bovine serum in the presence or absence of the indicated
concentrations of OME. At the bottom side of each dish, three
arbitrary places were marked where the width of the wound
was measured with an inverted microscope (objective x 10).
Wound closure was expressed as the average ± SEM of the
difference between the measurements at time zero and the
4-10 h time period considered.
Migration Chamber Assay.  5 x 104 cells were seeded in
the upper chamber, HTS multiwell insert system (BD
Biosciences, Franklin Lakes, NJ, USA), in serum-free medium,
with or without OME and migration assay was carried out
according to the manufacturer’s instruction. Serum-containing
medium was added to the lower chamber to act as a
chemotactic attractant. After 6 hours of incubation, cells were
washed with PBS, fixed with formaldehyde. Cells were then
stained with 1% crystal violet for 10 minutes. After washing with
PBS, cells from at least 5 different random fields were counted
under a microscope.
Cellular viability.  Cells were seeded in triplicate in 96-well
plates at a density of 5,000 cells / well. After 24h of culture,
cells treated with or without OME and incubated for the
indicated time period. Cell viability was determined using a
CellTiter-Glo Luminescent Cell Viability assay (Promega
Corporation, Madison, WI, USA), based on quantification of
ATP, which signals the presence of metabolically active cells.
Luminescent signal was measured using Berthold FB12
Luminometer. Data were presented as proportional viability (%)
by comparing the treated group with the untreated cells, the
viability of which is assumed to be 100%.
Aggregation Assay.  Growing cells were detached using
2mM EDTA in calcium magnesium-free PBS (CMF-PBS). A
cell suspension of 1 x 106 cells/ml was aliquoted into
microcentrifuge tubes, washed with PBS, resuspended in 1m
culture media and incubated with or without OME on a rocker
for 1 h at 37°C. Cells were then fixed with 1% formaldehyde
and pictures taken under an inverted microscope (Olympus
IX71). Aggregation was calculated as previously reported [34]
using the following equation: % aggregation=(1-Nt/Nc)x100,
where Nt and Nc represent the number of single cells in treated
or untreated groups, respectively.
Adhesion Assay.  Adhesion of MDA-MB-231 to HUVECs
was performed as previously described [35] with minor
modification. Briefly, cell culture plates were coated with
collagen and HUVECs grown to confluent monolayers. TNF-α
(25ng/ml) was added for 6 hours to stimulate HUVECs prior to
the addition of MDA-MB-231 cells. MDA-MB-231 transfected
with Renilla luciferase were resuspended in HBSS containing
1% BSA at a concentration of 2x105 cells/ml. 150 µl of this cell
suspension was added to the upper chamber containing
confluent HUVECs in the absence or presence of OME. After 1
hour, unattached cells were removed by gently washing the
plates three times with PBS. Adherent cells were lysed using a
luciferase lysis buffer (Promega, Madison, WI, USA) and light
units measured according to the manufacturer instructions.
Matrigel invasion assays.  Invasion assay was performed
as previously described [33]. The invasiveness of the MDA-
MB-231 cell treated with the indicated concentrations of OME
was tested using BD Matrigel Invasion Chamber (8-µm pore
size; BD Biosciences, Bedfrord, MA, USA) according to
manufacturer’s instructions. Briefly, MDA-MB-231 (1 x 105)
cells placed in 0.5 mL of media containing vehicle or the
indicated concentrations of OME were seeded into the upper
chambers of the system; the bottom wells in the system were
filled with DMEM complemented with 10% foetal bovine serum
as a chemo-attractant and then incubated at 37°C for 24h.
Non-penetrating cells were removed from the upper surface of
the filter with a cotton swab. Cells that have migrated through
the matrigel were fixed with 4% formaldehyde, stained with
DAPI and counted in 6 random fields under a microscope. For
quantification, the assay was done in duplicates and repeated
three times.
Measurement of matrix metalloproteinases by
ELISA.  Cells were seeded in 6-well plates in the absence of
vehicle or OME for 24 hours. The conditioned medium was
collected and the levels of secreted MMP-2 and MMP-9 were
determined using immunoassay kits (Invitrogen, Camarillo, CA,
USA) according to the manufacturer’s protocol. Experiments
were repeated three times and the average of three means is
represented ± SEM.
Gelatin zymography.  Gelatin zymography was performed
as previously described [36]. Briefly, MDA-MB-231 (2.5 x 106)
cells were incubated in serum-free DMEM for 24 h in the
presence of vehicle or OME (150 and 300 µg/mL). The
conditioned medium was collected, concentrated and 30 µg of
total protein was resolved in 10% polyacrylamide gels
containing 0.1% gelatin. After electrophoresis, the gels were
washed for 1 h in 2.5% (v/v) Triton X-100 to remove SDS and
then incubated overnight at 37 °C in 50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 0.5 mM ZnCl2 and 10 mM CaCl2 to allow
proteolysis of the gelatin substrate. Bands corresponding to
activity were visualized by negative staining using 0.5%
Coomassie brilliant blue R-250 (Bio-Rad, Hercules, CA, USA).
Representative results from two independent experiments are
shown. Densitometry was performed using ImageJ software
and band density was normalized to the non-specific band
staining on the gel.
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Immunofluorescence staining.  immunofluoreacence
staining was performed as previously described [31]. MDA-
MB-231 cells (3 x104) were grown in complete media on 4 well
labtek chamber slide (Nunc, Rochester, NY, USA) for 24 h,
then treated with ethanol as control or OME extract for 24 h at
the indicated concentrations. Cells were then fixed in 10%
formalin solution (4% paraformaldehyde) (Sigma-Aldrich, Saint-
Quentin Fallavier, France) for 5 min at RT followed by
permeabilization in PBS containing 0.1% Triton X-100 for 5 min
at RT. Cells were then washed three times with PBS, blocked
with 5% nonfat dry milk in PBS for 30 min at RT and incubated
with the primary antibody diluted, at the concentration
suggested by the manufacturer, in 1% nonfat dry milk/PBS
overnight at 4°C. Following overnight incubation, cells were
washed three times with PBS and placed for 1 h at RT in the
presence of fluorescein-conjugated secondary antibody diluted
at 1:200 in 1% nonfat dry milk/PBS. After washing with PBS,
cells were mounted in Fluoroschield with DAPI (Sigma-Aldrich,
Saint Louis, MO, USA) and examined under Nikon Ti U
fluorescence microscope.
Quantitative Immunoassay for Human Vascular
Endothelial Growth Factor (VEGF).  MDA-MB-231 cells (1.5
x 105) were seeded in 24-well plates. The conditioned medium
was collected and the level of VEGF therein measured using a
VEGF enzyme-linked immunosorbent assay kit (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
protocol. Assays were performed in triplicates and three
independent experiments were performed. Data are presented
as mean values ± SEM.
Quantification of Nitrate/Nitrite production.  The amount
of Nitrate/Nitrite production was determined with a colorimetric
ELISA kit (Cayman Chemical, Ann Arbor, Michigan, USA),
which is based on the Griess reaction, according to the
manufacturer’s instructions. The value of nitrate/nitrite
presented is the total value measured in the presence of cells
minus the value determined from the media alone in the
absence of any growing cells.
Luciferase activity.  MDA-MB-231 cells were seeded in 12-
well plates the day before transfection. Cells were then
transfected with the E-cadherin luciferase reporter expression
plasmid [37] using Lipofectamine 2000 (Life Technologies, Inc.
Grand Island, NY, USA) according to the manufacturer’s
protocol. Briefly, cells were allowed to recover for 4 hours after
transfection in OPTI-MEM (Life Technologies, Inc. Grand
Island, NY, USA) which was then replaced with complete
medium. Luciferase activity was measured using Dual
Luciferase Reporter Assay System (Promega, Madison, WI,
USA). Renilla luciferase reporter was used as an internal
control, to which firefly luciferase values were normalized.
Experiments were repeated three times and the average of
three means is represented ± SEM.
Transendothelial Migration Assay.  Transendothelial
migration of MDA-MB-231 through HUVEC was performed as
previously described [29]. Briefly, transwell filters were coated
with collagen and allowed to dry overnight. HUVECs (2 X 105/
well) were then seeded onto the rehydrated membrane and
allowed to grow until a confluent monolayer is formed. Where
mentioned, TNF-α (25ng/ml) was added for 6 hours to
stimulate HUVECs. Then, MDAMB 231 cells (1 x 106) were
then loaded on top and incubated overnight in the absence or
presence of OME. Cells on the upper chamber were removed
with a cotton swab, whereas MDA-MB-231 on the bottom were
stained and quantified as previously reported [29].
RNA extraction and RT-PCR.  Total RNA from vehicle- or
OME-treated MDA-MB-231 cells were prepared using Trizol
reagent as described by the manufacturer (Life Technologies,
Inc. Grand Island, NY, USA). RNA expression of MMP-2 and
MMP-9 was determined by RT-PCR. RT-PCR was performed
using the Qiagen OneStep RT-PCR kit (Qiagen, Hilden,
Germany) according to manufacturer’s instruction. Equal
amounts of RNA (500 ng) were used as templates in each
reaction. The sequences of specific primers were as follows:
MMP-2 sense, 5′-TCTCCTGACATTGACCTTGGC -3′, and
antisense: 5′-CAAGGTGCTGGCTGAGTAGATC -3′; MMP9
sense, 5′- TTGACAGCGACAAGAAGTGG-3′, and antisense,
5′- CCCTCAGTGAAGCGGTACAT-3′; GAPDH sense, 5′-
GGCCTCCAAGGAGTAAGACC -3′, and antisense: 5′-
AGGGGTCTACATGGCAACTG-3′. The PCR products were
separated by 1.5% agarose gel and visualized by ethidium
bromide staining. Representative results from two independent
experiments are shown.
Nuclear and whole Cell extract and Western Blotting
analysis.  Cells (1.8 x 106) were seeded in 100mm culture
dishes and cultured for 24h before addition of various
concentrations of OME extract. For whole cell lysates, after
incubation for the indicated times, cells were washed twice with
ice-cold PBS, released by scrapping, pelleted and lysed in
RIPA buffer supplemented with protease/phosphatase inhibitor
cocktail. Following incubation for 30 min on ice, the cell lysate
was obtained by centrifugation at 14,000 rpm for 20 min at 4°C.
Nuclear extract were prepared from vehicle- or OME-treated
MDA-MB-231 cells using the NE-PER extraction reagents
(Thermo Scientific, Rockford, IL, USA) according to the
manufacturer’s instructions. Protein concentration of lysates
was determined by BCA protein assay kit (Thermo Scientific,
Rockford, IL, USA) and the lysates were adjusted with lysis
buffer. Aliquots of 30 µg of total proteins were resolved onto
10-12% SDS-PAGE. Proteins were transferred to nitrocellulose
membranes (Thermo Scientific, Rockford, IL, USA) and
blocked for 1 h at room temperature with 5% non-fat dry milk in
TBST (TBS and 0.05% Tween 20). Incubation with specific
primary antibodies was performed in blocking buffer overnight
at 4°C. Horseradish peroxidise-conjugated anti-IgG was used
as secondary antibody. Immunoreactive bands were detected
by ECL chemiluminescent substrate (Thermo Scientific,
Rockford, IL, USA). Membrane stripping by incubating the
membrane in Restore western blot stripping buffer (Thermo
Scientific, Rockford, IL, USA) according to the manufacturer’s
instructions.
Chick embryo tumor growth and metastasis assay.  The
chick embryo tumor growth assay was performed as previously
described [38] with slight modifications. According to the
French legislation, no ethical approval is needed for scientific
experimentations using oviparous embryos (decree n°
2013-118, February 1, 2013; art. R-214-88). Animal work was
done under animal experimentation permit N° 381029 to jean
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Viallet and animal experimentation permit N° B3851610001 to
Institut Albert Bonniot. Briefly, Fertilized White Leghorn eggs
(Société Française de Production Agricole, St.-Brieuc, France),
were incubated at 38°C with 60% relative humidity for 10 days.
At stage E10, the chorioallantoic membrane (CAM) was
dropped by drilling a small hole through the eggshell into the air
sac and a 1 cm2 window was cut in the eggshell above the
CAM. Cultured MDA-MB-231-GFP were detached by
trypsinization, washed with complete medium and suspended
in serum free DMEM. A 50 µl inoculum of 1 X 106 MDA-
MB-231-GFP cells was added onto the CAM of each egg (eggs
were randomized in 4 groups of 15). One day later, tumors that
began to be detectable were treated every second day at E11,
E13, E15 and E17 by dropping 100 µl of either OME (300
µg/mL or 450 µg/mL), colchicine (2µM) or 0.02% ethanol
(vehicle) in PBS onto the tumor. At E19 the upper portion of the
CAM was removed, transferred in PBS and the tumors were
then carefully cut away from normal CAM tissue and weighted.
In parallel, a 1cm2 portion of the lower CAM was collected to
evaluate the number of nodules, containing GFP-expressing
cells. The fluorescent nodule were visualized in situ using
whole mounts of tissue fixed in 4% formaldehyde in PBS and
flattened between a hollow glass slide and a thick coverslip. In
order to number the nodule, a thorough and complete visual
scan of the piece of the lower CAM was done using fluorescent
microscope. Chick embryos were sacrificed by decapitation.
Statistical analysis.  Results were expressed as means ±
S.E.M. of the number of experiments. A Student’s t-test for
paired or unpaired values was performed and a p value of <
0.05 was considered statistically significant.
Results
Origanum majorana attenuates the migration ability of
the MDA-MB-231 breast cancer cells
We have recently reported that OME induces cell cycle
arrest and apoptosis in MDA-MB-231 cells [31]. Because cell
migration plays a crucial role in tumour metastasis, we sought
to investigate whether OME affects the migration behaviour of
MDA-MB-231 cells, we first measured the migration ability of
these cells by using wound-healing migration assay. For this
purpose, were performed the test with concentrations of OME
and periods of treatment that were previously shown to be non-
cytotoxic to the MDA-MB-231 [31]. As shown in Figure 1A and
1B, OME treatment significantly inhibited wound healing
cellular migration of MDA-MB-231 cells in a concentration-
dependent manner. The ability of OME to inhibit the migration
of MDA-MB-231 cells was also measured by using the Boyden
chamber transwell assay. For this purpose, MDA-MB-231 cells
were seeded in the upper wells with or without 300 µg/mL
OME. As it is shown in Figure 1D and 1E, the number of OME-
treated cells that has migrated to the lower chamber, after 6 h
treatment, was significantly reduced by approximately three
fold compared to the number of vehicle-treated cells. Cell
viability of the OME-treated cells at the concentrations and time
tested was not affected (Figure 1C) thus confirming that the
inhibitory effect on the MDA-MB-231 cells motility was not due
to a cytotoxic effect of OME. Taken together our data confirm
the inhibitory effect OME on the migration potential of MDA-
MB-231 cells.
Origanum majorana promotes cell-cell aggregation and
induces E-cadherin upregulation in MDA-MB-231 cells
Lost capacity for homotypic adherence is also associated
with cancer cell metastasis. To determine whether OME would
affect the cell-cell adherence behaviour of MDA-MB 231, cell
aggregation assay was performed on vehicle and OME-treated
cells. We found that OME significantly increased the ability of
MDA-MB-231 cells to form cell aggregates visible as early as
30 min post-treatment (Figure 2A). It is known that loss of E-
cadherin expression promotes tumor progression and
metastasis while its overexpression prevents invasion of tumor
cells. We therefore sought to examine the expression of E-
cadherin in MDA-MB-231 cells in response to OME exposure.
We first examined the protein level of E-cadherin in MDA-
MB-231 cells treated without and with OME. As it is shown in
Figure 2B, OME induced a significant increase of E-cadherin
protein in a concentration-dependent manner. This increase in
E-cadherin expression was further confirmed by
immunofluorescence staining (Figure 2C). The expression of E-
cadherin was mostly detected at the cells junctions.
Next we determined whether the effect of OME on E-
cadherin expression was mediated through a transcriptional
regulation. Toward this, transcription activity was measured in
cells transfected with a luciferase reporter gene containing E-
cadherin promoter and treated without or with OME. As shown
in Figure 2D, OME induced a concentration-dependent
increase in the luciferase activity, thus indicating that OME
positively regulates the expression of E-cadherin at the
transcriptional level. Taken together, our data clearly shows
that E-cadherin is upregulated by OME and further suggests
that the expression of this protein could account for the
inhibition of cellular migration and invasion.
Origanum majorana inhibits the invasive capacity of
MDA-MB-231 cells
Next, we examined the invasive potential of MDA-MB-231
cells in the Matrigel-coated Boyden chamber in the absence or
presence of 150 µg/mL OME. The number of OME-treated
cells that has passed through the Matrigel coated membrane
was markedly reduced by 55% (Figure 3, A and B), indicating
that OME can inhibit the invasiveness ability of the MDA-
MB-231 cells.
Origanum majorana suppresses the expression and the
activity of MMP-2 and MMP-9 and downregulates uPAR
in MDA-MB-231 cells
Matrix metalloproteinases (MMP) -2 and -9, among other
MMPs, are known to play an important role in breast cancer
cell invasion and metastasis. To test whether O. majorana
inhibits breast cancer cell invasion by affecting the expression
of MMP-2 and MMP-9, we decided to examine the protein
expression level of MMP-2 and MMP-9 in the conditioned
medium using OME-treated MDA-MB-231 cells. The protein
level of MMP-2 and MMP-9 (Figure 4A) was found to be
significantly reduced in response to OME treatment. RT-PCR
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Figure 1.  O. majorana extract inhibits the migration of the MDA-MB-231 human breast cancer cells.  (A) Confluent culture of
MDA-MB-231 cells were wounded by scratching with a pipette tip and the cells were incubated in DMEM supplemented with 10%
fetal bovine serum without and with indicated concentrations of OME. The wound was measured with an inverted microscope (x 100
magnification) and photographed. (B) Wound healing assay showing that OME inhibited the migration of MDA-MB-231 breast
cancer cells in dose-dependent manner. Values represent means ± SEM (n=3) of the difference between the measurements at time
zero and the 4-10 h time period considered. (C) Cell viability (in percent) determined by using CellTiter-Glo Luminescent Cell
Viability assay, after incubation of the exponentially growing cells with or without various concentrations of OME for 10 h. (D)
Boyden chamber transwell assay indicating that OME inhibited the migration of MDA-MB-231 cells. (E) Quantification of Migrated
MDA-MB-231 cells. Migrating cells from at least 5 different random fields were counted under a microscope. Values represent
means ± SEM, n=3. Student’s t test was performed to determine the significance (*p < 0.05, **p < 0.005 and ***p < 0.0005).
doi: 10.1371/journal.pone.0068808.g001
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analysis also revealed that the MMP-2 and MMP-9 mRNA level
was reduced in MDA-MB-231 cells upon treatment with OME
(Figure 4B) indicating that OME can inhibit the transcription of
MMP-2 and MMP-9 genes in these cells.
Next, we decided to examine the effect of OME on the
activity of MMP-2 and MMP-9. MDA-MB-231 cells were treated
with 150 and 300 µg/mL OME for 24 h in serum free DMEM,
the media was collected, concentrated and tested for MMP2
and MMP-9 activity by gelatin zymography. As it is shown in
Figure 4C, MMP-2 and MMP-9 activities were significantly
reduced in response to OME treatment. Altogether, our results
showed that OME significantly inhibits both, the expression and
the activities of MMP-2 and MMP-9.
The urokinase plasminogen activator (uPA) and its receptor
(uPAR) were also shown to play a crucial role in breast cancer
cell invasion and metastasis. Therefore, we examined whether
OME also alters the expression of uPAR. Western blot analysis
Figure 2.  O. majorana promotes cell-cell aggregation and upregulates E-cadherin expression.  (A) MDA-MB-231 cells were
incubated without or with 300 µg/mL OME and subjected to cell aggregation as described in Materials and Methods. Aggregated
cells were photographed under phase-contrast microscope (x 100 magnification). (B) Western blotting analysis of E-cadherin
expression in OME-treated MD-MB-231 cells. Cells were treated with vehicle or increasing concentrations of OME (150, 300 and
450 µg/mL) for 24 h, then whole cell extracts were subjected to Western blot analysis for E-cadherin and β-actin (loading control)
proteins. (C) MDA-MB-231 cells were treated with 450 µg/mL OME for 24 h, fixed permeabilized, and then processed for
immunofluorescence using antibody against E-cadherin protein. DAPI was used as a nuclear stain. (D) Following transfection with a
luciferase reporter gene containing E-cadherin promoter, MDA-MB-231 cells were treated for 24 h with or without OME, lysed, and
luciferase activity was measured. The luciferase activities were normalized to the levels of internal Renilla luciferase activity.
Experiments were performed in triplicate and repeated three times. Values represent means ± SEM, n=3. Student’s t test was
performed to determine the significance (*p < 0.05 and **p < 0.005).
doi: 10.1371/journal.pone.0068808.g002
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clearly shows that the expression level of uPAR was markedly
decreased in OME-treated MDA-MB-231 cells (Figure 4D).
Origanum majorana decreases adhesion of MBA-
MB-231 to HUVEC and downregulates the expression of
ICAM-1 in the breast cancer cells
The attachment of tumor cells to endothelial blood vessels is
also crucial event in the process of metastasis. The effect of
OME on MDA-MB-231 cell adhesion to TNF-α stimulated
HUVECs was then investigated by co-incubating both cell
types for 1 h with or without various concentrations of OME.
Figure 5A shows that OME significantly inhibited the adhesion
of MDA-MB-231 cells to HUVECs in concentration-dependent
manner.
Because the intercellular adhesion molecule (ICAM)-1, has
been shown to play an important role in the adhesion of cancer
cells to endothelial cells and therefore in metastasis, we sought
to examine whether OME affects the expression of this
adhesion molecule in MDA-MB-231 cells. Toward this aim,
cells were treated with various concentrations of OME and the
protein level of the ICAM-1 was determined by Western
blotting. As it is shown in Figure 5B, the level of ICAM-1 protein
decreased in concentration-dependent manner in OME-treated
MDA-MB-231 cells. Taken together, our results suggest that
OME exerts an inhibitory effect on the adhesion of MDA-
MB-231 cells to HUVEC and that this effect is associated with a
downregulation of ICAM-1protein.
Figure 3.  O. majorana inhibits the invasive activity of MDA-MB-231 cells.  (A) MDA-MB-231 cells were incubated for 24 h with
or without OME (150 µg/mL) and LY294002 (20 µM). Cells that invaded into the matrigel were scored as described in Materials and
Methods. (B) Quantification of invaded MDA-MB-231 into the matrigel. Values represent means ± SEM, n=3. Student’s t test was
performed to determine the significance (*p < 0.05 and **p < 0.005).
doi: 10.1371/journal.pone.0068808.g003
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Origanum majorana inhibits transendothelial migration
of MDA-MB-231 through TNF-α-stimulated HUVECs
Since the migration of tumor cells through the vascular
endothelium is another crucial event in the metastasis process,
we used the transendothelial migration assay to investigate the
effect of OME on the ability of MDA-MB-231 cells to migrate
across a monolayer of endothelial (HUVEC) cells. As seen in
Figure 6, the transendothelial migration of OME treatment
through the monolayer of HUVEC was significantly reduced by
the treatment with OME in a dose-dependent manner.
Origanum majorana suppresses VEGF production in
HUVECs and MDA-MB-231 cells
Tumor growth and metastasis critically depend on
angiogenesis. VEGF, a pro-angiogenic growth factor, has been
shown to play an important role in this process. Thus, we
investigated the effect of OME on the production of VEGF by
both the MDA-MB-231 and endothelial cells (HUVEC) without
or with the presence of TNF-α. We first examined the effect of
OME of basal expression level of VEGF in MDA-MB-231 cells.
Cells we grown with various concentrations of OME and the
conditioned medium were collected and the level of VEGF
measured by ELISA. Data shown on Figure 7A revealed that
treatment with 300 and 450 µg/mL OME for 24 h markedly
Figure 4.  The effect of O. majorana on MMP-2, MMP-9 and uPAR in MDA-MB-231 cells.  (A) Effects of OME on the secretions
of MMP-2 and MMP-9 in the collected conditioned medium of OME-treated MDA-MB-231 cells. The levels of secreted MMP-2 and
MMP-9 were determined using immunoassay kits as described in Materials and Methods. Experiments were repeated three times
and the average of three means is represented ± SEM. Student’s t test was performed to determine the significance (*p < 0.05 and
**p < 0.005). (B) Effects of OME one the expression of MMP-2 and MMP-9 mRNA. MDA-MB-231 cells were treated with OME (150
and 300 µg/mL) for 24 h and then subjected to RT-PCR to analyze the mRNA level of MMP-2 and MMP-9. GAPDH was used as an
internal control. (C) Activities of MMP-2 and MMP-9 in OME-treated MDA-MB-231 cells. Cells were treated with 150 and 300 µg/mL
OME for 24 h and then subjected to gelatin zymography, as described in Materials and Methods, to analyze the activities of MMP-2
and MMP-9. (D) Western blotting analysis of uPAR expression in OME-treated MD-MB-231 cells. Cells were treated with vehicle or
increasing concentrations of OME for 24 h, then whole cell extracts were subjected to Western blot analysis for uPAR and β-actin
(loading control) proteins.
doi: 10.1371/journal.pone.0068808.g004
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reduced the secretion of VEGF by MDA-MB-231 cells. VEGF
level dropped from 1300 pg/mL in vehicle treated to 800 and
400 pg/mL respectively. To further confirm the inhibition of
VEGF production in breast cancer cells, we measured the level
of VEGF in MDA-MB-231 cells that were first treated with
various concentration of OME and then stimulated with TNF-α.
As shown in Figure 7B, the production of VEGF was enhanced
in TNF-α - stimulated (2600 pg/mL) compared to vehicle-
treated (1500 pg/mL) MDA-MB-231 cells. However, VEGF
production was significantly reduced in concentration-
dependent manner by OME (Figure 7B). Next, we examined
VEGF production in HUVECs. As expected, HUVEC cultured in
the absence of TNF-α produced low level of VEGF (20 pg/mL),
while in the presence of TNF-α, VEGF production increased to
approximately 120 pg/mL (Figure 7C). Exposure of HUVEC to
OME also led to a concentration -dependent suppression of
VEGF production (Figure 7C).
Origanum majorana inhibits the phosphorylation of IκB,
downregulates the nuclear level of NFκB
The NFκB signaling pathway is known to regulate the
expression of various genes involved in tumor cells invasion.
Figure 5.  Inhibition of adhesion of MDA-MB-231 cells to HUVEC by O. majorana.  (A) MDA-MB-231 cells were treated
overnight with vehicle or OME then seeded on top of the confluent TNF-α stimulated HUVECs and allowed to adhere for 60 min as
described in Materials and Methods. The adhesion of MDA-MB-231 cell is represented as percentage of cells that have adhered to
HUVECs. (B) Western blotting analysis of ICAM-1 expression in OME-treated MD-MB-231 cells. Cells were treated with vehicle or
increasing concentration of OME (150, 300 and 450 µg/mL) for 24 h, then whole cell extracts were subjected to Western blot
analysis for ICAM-1 and β-actin (loading control) proteins.
doi: 10.1371/journal.pone.0068808.g005
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To investigate the effect of OME on the activation of NFκB
signaling pathway, we first examined, by Western blotting, the
phosphorylation status of IκB in OME-treated MDA-MB-231
cells. We found that OME drastically inhibited the
phosphorylation of IκB (Figure 8A). Moreover, we found that
OME remarkably reduced the level of nuclear NFκB (Figure
8B). Taken together, our data clearly indicates the OME exert
its effects at least partly through an inhibition of the NFκB
signaling pathway.
Origanum majorana reduces Nitric Oxide (NO)
production in MDA-MB-231 cells
Nitric oxide (NO) signaling has also been shown to promote
breast tumor growth and metastasis by altering the expression
of genes implicated in cellular migration, invasion and
angiogenesis [39–41]. To test whether OME could affect the
level of NO, the amount of Nitrate/Nitrite production was
determined by ELISA in vehicle and OME-treated MDA-
MB-231 cells. Results shown in Figure 9 clearly show that
OME decreased NO production in a concentration-dependent
manner in MDA-MB-231 cells, thus suggesting that OME could
also exert its anti-metastatic effect by modulating the level of
NO in breast cancer cells.
Origanum majorana inhibits tumor growth and
metastasis in chick embryo tumor growth and
metastasis assay
To further confirm the in vitro anti-breast cancer activities of
O. majorana, we decided to investigate its effect on tumor
growth in vivo by using the chick embryo model. MDA-MB-231
cells were grafted on the chorioallantoic membrane (CAM) and
formed tumors were treated every 48 h with vehicle, colchicine
(2 µM) or increased concentrations of OME (300 and 450 µg/
mL). At E 19, tumors were recovered from the upper CAM and
weighted. As it is shown in Figure 10 A and B, OME
significantly inhibited tumor growth compared with the vehicle
treatment. In fact, concentrations of 300 and 450 µg/mL OME
led to reduced tumor growth by 55 and 60% respectively.
Similar effect (65% inhibition) was obtained with 2 µM
colchicines. Toxicity was evaluated by comparing the number
of dead embryos in OME-treated and control (vehicle- and
colchicine-treated) embryos. We found that OME showed no
toxicity to the embryo (data not shown).
We next assessed for the ability of OME to inhibit metastasis
by counting the number of nodules in the lower CAM in vehicle,
colchicines and OME treated tumors. An average of 6.6
nodules were counted in the lower CAM of vehicle-treated
chick embryo, while an average of 1.1 nodules only were
counted in 300 and 450 µg/mL OME-treated embryo (Figure
10C). All together, our data clearly demonstrates that OME
could efficiently inhibit breast tumor growth and metastasis in
vivo.
Discussion
Tumor invasion and metastasis is a multistep process
involving cell adhesion, proteolytic degradation and migration
through the ECM and angiogenesis. Common cancer treatment
drugs aim at blocking cell cycle progression, inducing cell
death and/or inhibiting tumor migration and invasion. Cancer
chemoprevention through these events has been reported for
Figure 6.  O. majorana inhibits the migration of MDA-MB-231 cells across monolayer of TNF-α activated HUVECs.  Confluent
monolayers of HUVECs were pre-incubated with TNF-α (25 ng/mL) for 6 h, and transendothelial migration was evaluated after
overnight incubation at 37°C. Values represent means ± SEM, n=3. Student’s t test was performed to determine the significance (*p
< 0.05).
doi: 10.1371/journal.pone.0068808.g006
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several natural compounds [15,17,42–44]. Nowadays, there is
a growing interest in combination therapy using multiple
anticancer drugs affecting several targets/pathways. Herein,
we demonstrate for the first time that O. majorana, at non-
cytotoxic concentrations, possesses potent anti-metastatic
activities against the highly invasive triple negative breast
cancer cell line, MDA-MB-231. In fact, O. majorana efficiently
inhibited the migratory abilities and induced homotypic
aggregation of MDA-MB-231 cells, associated with an
upregulation of E-cadherin expression. We also showed that O.
majorana not only decreased the adhesion of MDA-MB-231 to
HUVECs as well as their transendothelial migration, but also
inhibited the secretion of the pro-angiogenic factor VEGF from
both endothelial and breast cancer cells. In addition we
demonstrate that O. majorana suppressed the expression and
the activities of MMP-2 and MMP-9 and downregulated the
expression of uPAR and ICAM-1. O. majorana also blocked
IκB-α/NFκB and reduced Nitric Oxide (NO) production, both
signalings involved in cancer cell invasion. Moreover, we
demonstrated that O. majorana significantly inhibited tumor
growth and metastasis in vivo in chick tumor growth assay.
It is well known that disruption of cell-cell adhesion during
cancer progression is the initial stage required for the
acquisition of invasive properties. Decreased cell-cell adhesion
in cancer cells is often characterized by diminished expression
of E-cadherin. Indeed, E-cadherin, a calcium-dependent, cell
adhesion molecule, is considered as a tumor suppressor in
breast cancer [45]. A decrease in E-cadherin expression is a
critical and necessary event required in the disruption of cell-
cell adhesion and thus for the acquisition of invasive phenotype
of various tumors including breast cancer. In fact,
downregulation or loss of E-cadherin during cancer progression
is associated with aggressive behavior of the tumor and poor
prognosis [46]. Conversely, expression of E-cadherin led to a
Figure 7.  Reduction of VEGF secretion in O. majorana-treated HUVECs and MDA-MB-231 cells.  (A) Quantification of basal
level of VEGF secretion in conditioned medium from vehicle or OME-treated MDA-MB-231 cells. Cells were treated with vehicle or
the indicated concentrations of OME for 24 h and then the secreted VEGF in the conditioned medium was analyzed by ELISA.
Reduction of VEGF secretion in TNF-α induced MDA-MB-231 cells (B) and HUVEC (C) cultured in presence of vehicle or indicated
concentrations of OME. VEGF secretion was quantified as by ELISA as described above. Data represents means ± SEM of three
independent experiments. Student’s t test was performed to determine the significance (*p < 0.05, *p < 0.005 and **p < 0.0005).
doi: 10.1371/journal.pone.0068808.g007
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reduced progression and invasion of breast cancer cells [47]. In
the present study, we demonstrated that O. majorana inhibited
cell migration and promoted homotypic cell-cell aggregation
and induced overexpression of E-cadherin in the MDA-MB-231
cells. We postulate that O. majorana exerts its anti-migratory
effect on breast cancer cells, at least partly, through
reactivation of the expression of E-cadherin gene. In fact we
showed that OME was able to induce transactivation of E-
cadherin promoter in transfected cells (Figure 3D). Induction of
E-cadherin expression promotes then homotypic aggregation
of OME-treated MDA-MB-231 cells. Thus, E-cadherin
overexpression is one of possible mechanism by which O.
majorana exerts its anti-invasive effect on the MDA-MB-231
cells. Recent studies showed that treatment with histone
Figure 8.  Effect of O. majorana on NFκB signaling.  (A) Western blot analysis of the phosphorylation status of IκBα. MDA-
MB-231 cells were treated with vehicle or increasing concentration of OME (300 and 450 µg/mL) for 24 h, then whole-cell extracts
were subjected to Western blot analysis for IκBα and β-actin (loading control) proteins. (B) MDA-MB-231 cells were treated with
vehicle or indicated concentrations of OME for 24 h and then nuclear extracts were prepared as described in Materials and Methods
and subjected to Western blot analysis for p65 (NFκB) and β-actin (loading control) proteins.
doi: 10.1371/journal.pone.0068808.g008
Figure 9.  Reduction of Nitric Oxide (NO) production in O. majorana-treated MDA-MB-231 cells.  Quantification of NO levels in
OM-treated MDA-MB-231 cells. Cells (1.5 X 105) were treated with vehicle or indicated concentrations of OME for 24 h and Nitrate/
Nitrite production was quantified as described in Materials and Methods. Data represents means ± SEM of three independent
experiments carried out in triplicate. Student’s t test was performed to determine the significance (*p < 0.05, *p < 0.005 and ***p <
0.0005).
doi: 10.1371/journal.pone.0068808.g009
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deacetylase inhibitors such as SAHA and trichostatin A
strongly inhibited the migration and invasion of breast and
prostate cancer cells and caused an upregulation of E-cadherin
[48,49]. Histone deacetylases (HDAC) inhibitors, promising
anticancer agents, have been shown to mediate their effects by
activating the transcription of specific genes through histones
hyperacetylation. Interestingly, we have recently shown that O.
majorana induces hyperacetylation of histone H3 and H4 at
non-cytotoxic concentrations [31]. Moreover, O. majorana has
been shown to contain luteolin [50], a dietary flavonoid with
histone deacetylase inhibitor activity, which was also shown to
inhibit the invasive potential of MDA-MB-231 cells [33]. Based
on these findings, we can suggest that one possible
mechanism by which O. majorana exerts its anti-migratory and
anti-metastatic effects on MDA-MB-231 involves an
upregulation of E-cadherin gene expression through histone
hyperacetylation. However, at this stage, we cannot rule out
the involvement of other mechanism(s) involved in this
regulation. Further investigation will be needed to decipher the
exact mechanism by which O. majorana exert its effect on E-
cadherin expression.
The dissemination of cancer cells from the primary tumor is
another crucial event in the process of cancer invasion and
metastasis, which involves the degradation of the ECM and the
components of the basement membrane through proteases. Of
these proteases, MMPs such as MMP-2, MMP-9 and the uPA
are thought to play a key role in cancer cell invasion and
metastasis [51,52]. It has been showed that increasing
Figure 10.  Anti-tumor growth and anti-metastatic activity of O. majorana on breast tumor in chick embryo chorioallantoic
membrane model system.  (A) MDA-MB-231 (1 x 106) cells were grafted on the CAM of 10 day (E10) chick embryo. Tumors were
treated every 48 h with OME as described in Materials and Methods. At E19, tumors were collected and weighted. (B) Quantification
of tumor weight in vehicle, colchicine and indicated concentrations of OME-treated chick embryo. (C) Anti-metastatic effect of O.
majorana. Quantification of nodules observed in the lower CAM of chick embryo treated with vehicle, colchicine or indicated
concentrations of OME. Columns represents mean; bars represents SEM. *** significantly different at p < 0.0005.
doi: 10.1371/journal.pone.0068808.g010
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expression of MMPs in breast cancer cells correlates with
increasing aggressiveness of breast cancer cell growth and
metastatic potential [53]. Therefore, inhibiting the activity or the
expression of these proteases can be considered as potential
therapeutic targets against breast cancer. Interestingly, here
we clearly demonstrate that O. majorana exerts its anti-
invasive affect against MDA-MB-231 cells by significantly
downregulating the expression of uPAR, MMP-2 and MMP-9
and decreasing the activity of these two proteases and
consequently reducing ECM degradation.
The ability of tumor cells to metastasize also largely depends
on their ability to adhere and transmigrate though endothelial
cells. Cancer cell-endothelial cell interaction is mediated by
various adhesive molecules such as intracellular adhesion
molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1) and E-selectin [54].
Studies have shown that the level of ICAM-1 protein
expression on the cell surface positively correlated with
metastatic potential of several breast cancer cell lines [8].
Moreover, downregulation of ICAM-1 at the protein and mRNA
levels strongly inhibited human breast cancer cell invasion [8].
Tanshimone I, a natural compound derived from medicinal
plant, Salvia miltiorrhiza, efficiently inhibited the adhesion of
MDA-MB-231 cells to HUVECs by downregulation the
expression of ICAM-1 and VCAM-1 [55]. Recent study revealed
that ICAM-1 expression was associated with a more
aggressive breast tumor phenotype [56]. Based on these
findings, ICAM-1 represents a potential target in breast cancer
treatment. Our study revealed that O. majorana was able to
reduce the expression level of ICAM-1 protein in MDA-MB-231
cells and blocked their adhesion to the human vascular
endothelial cells (HUVECs). Hence, we propose that
downregulation of ICAM-1 expression could be one mechanism
by which O. majorana blocks MDA-MB-231 cells capabilities to
adhere to HUVECs and consequently preventing their
metastasis.
Angiogenesis, a process by which new blood vessels forms,
is crucial for tumor growth and metastasis. Blockade of
angiogenesis can inhibit both tumor growth and metastasis
[57]. Thus inhibition of angiogenesis can be considered as a
promising strategy in cancer therapy [57,58]. One possible way
to block angiogenesis is to target pro-angiogenic factors
secreted by tumor cells. VEGF is the major pro-angiogenic
protein expressed in 60% of breast cancer patients at the time
of first diagnosis [59]. Interestingly, we found that O. majorana
significantly reduced the production of VEGF in both HUVECs
and MDA-MB-231 cells and thus suggesting that OME not only
inhibit breast cancer cell invasion but could also block
angiogenesis.
The NFκB signaling pathway is known to regulate the
expression of various genes involved in the process of tumor
metastasis. Elevated levels of NFκB are frequently detected in
breast cancer cells. Studies showed that inhibition of NFκB
activity could suppress metastasis in breast cancer cells. In
fact, studies showed that inactivation of NFκB in MDA-MB-231
breast cancer cells inhibit the expression of many downstream
target genes involved in tumor metastasis such as MMP-2 [53],
MMP-9 [16,60,61], VEGF [61], ICAM-1 [16] and uPAR [16].
The phosphorylation of IκB, by the IKKβ subunit of the IKK
serine kinase complex, is a crucial step in the activation of
NFκB. In fact, phosphorylation of IκB triggers its
polyubiquitination and proteasome-mediated degradation with
consequent NFκB nuclear localization [62]. Nuclear NFκB can
then upregulate the transcription of its target genes. Hence,
one way to inactivate the constitutively activated NFκB
signaling in cancer cells is to block the phosphorylation of Iκb
by inactivating the IKK complex. Interestingly, in the present
work, we demonstrated that O. majorana inhibited the
phosphorylation of IκB and reduced the protein level of nuclear
NFκB and thus suggesting that O. majorana might negatively
regulate the activity of NFκB possibly by affecting the activity of
the IKK complex. It is noteworthy to mention that O. majorana
significantly reduced the expression of several NFκB
downstream target genes (MMP-2, MMP-9, uPAR, ICAM-1 and
VEGF) involved in tumor metastasis. It appears then, that the
inhibitory effect on NFκB could account in the anti-metastatic
effects of O. majorana.
Nitric Oxide (NO), synthesized by several nitric oxide
synthases (NOSs), nNOS/NOS-1, iNOS/NOS2 and eNOS/
NOS3 is a signaling molecule that regulates several
physiological responses such as vasodilatation, cell migration,
immune reactions and apoptosis [55]. Interestingly, various
studies have shown that NO can both promote and inhibit
tumor progression and metastasis. The pro- or anti-tumorigenic
activities of NO have been related to the p53 status [41,63]. It
has been shown that NO-mediated apoptosis in leukemia cells
requires wild-type p53 [64]. On the other hand, it has been
shown that iNOS/NOS2 expressing carcinoma cells with
mutant p53 have accelerated tumor growth and increased
VEGF production [65]. NO was shown to promote cancer
progression through an activation of oncogenic signaling
pathways including the extracellular signal-regulated kinases
(ERK) 1/2, phosphoinositide 3-kinases (PI3K)/AKT, and cMyc
[32]. Recent studies showed that increased iNOS/NOS2 and
consequently NO production, predicted poor survival in women
with estrogen receptor α–negative (ER-negative) breast
tumors. Moreover, exposure to NO enhanced cell motility and
invasion of Estrogen Receptor negative ER(-) cells [66]. It
appears then that discovery of inhibitors targeting NO
production may be particularly efficacious against ER(-),
mutant p53 breast cancer patients. In the present study we
showed that O. majorana efficiently reduced the level of NO
production in the MDA-MB-231 in dose-dependent manner
suggesting that O. majorana might exert its anti-metastatic
effect, at least partly, by modulating the NO production in MDA-
MB-231 cells. As such, NO production may be an important
target for chemoprevention and therapy by O. majorana for the
ER(-), mutant p53 MDA-MB-231 cells.
In summary, this study clearly demonstrated, for the first
time, that O. majorana possess an anti-invasive and anti-
metastatic effects against the highly proliferative and highly
invasive human MDA-MB-231 breast cancer cell line by
modulating the activity and/or the expression of proteins
regulating the process of cellular migration, adhesion invasion
and angiogenesis such as E-cadherin, ICAM-1, MMP-2,
MMP-9, uPAR and VEGF at least partly through inhibition of
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the NFκB and NO signaling pathways. Our results also showed
that O. majorana inhibited tumor growth and metastasis in an in
vivo tumor growth assay. Thus, our current study along with
our previous findings, identify Origanum majorana as a
promising chemopreventive and therapeutic candidate that
inhibits breast cancer growth and metastasis by modulating the
expression and activities of several targets. Nowadays, there is
a growing interest in combination therapy using multiple
anticancer drugs affecting several targets/pathways, thus O.
majorana certainly merits a lot of attention for further
explorations to identify novel compounds for breast cancer.
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